Has anyone else seeing the announcement by the FDA on anti-TNF drugs relating to fungal infections? It certainly is not affecting the share price of arana negatively. The fact that art 621 is a small compound may read the news is a positive for the trial going forward. I am no expert in the field and am just putting the idea out for comment so all comments are welcome
AAH
arana therapeutics limited
fda
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)